Moderna (MRNA) has won a case against Pfizer (PFE) and BioNTech (BNTX) at the European Patent Office in its ongoing legal dispute to recoup pandemic profits, The Financial Times’ Oliver Barnes and Ian Johnston reports. The EPO’s Opposition Division ruled to uphold the validity of one of two disputed patents, according to the report. “We are pleased to announce that the European Patent Office decided to maintain the validity of Moderna’s EP949 patent, one of the key patents currently asserted against Pfizer and BioNTech in various European national courts,” Moderna told the publication, which notes that Pfizer has a nine-month window to lodge an appeal, which it said it may do.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA:
- Moderna initiated with an In Line at Evercore ISI
- Novavax (NASDAQ:NVAX) Explodes 50% Higher after Sanofi Deal
- Early notable gainers among liquid option names on May 13th
- Moderna says FDA does not expect to complete mRNA-1345 BLA review by May 12
- Moderna price target raised to $85 from $70 at Deutsche Bank